PE-backed Trinity buys Bell Canyon Consulting

Trinity, which is backed by Parthenon Capital Partners, has acquired Bell Canyon Consulting, which works with life sciences clients. No financial terms were disclosed.


WALTHAM, Mass.–(BUSINESS WIRE)–TRINITY, the global life sciences commercialization solutions provider, today announced it has acquired Bell Canyon Consulting to create a new combined offering that will address critical gaps in the market for improved data management and reporting. With the Bell Canyon acquisition, TRINITY will be able to provide both technical knowledge and subject matter expertise, improving data transparency, quality and access. The integration with Bell Canyon will advance TRINITY’s vision of providing evidence-based solutions and enhance TRINITY’S existing Commercial Data Solutions Suite. The new version of this offering will create a solution currently not available in the life sciences market.

“Bell Canyon’s master data management capabilities will enhance TRINITY’s Commercial Data Solutions, specifically designed for emerging life sciences companies,” said David Fitzhenry, CEO, TRINITY. “The master data management and software currently provided by Bell Canyon provides a robust and reliable solution for managing the growing, disparate data assets of their customers. This acquisition will expand our current offering for companies from early stage development through commercialization.”

TRINITY’s new Commercial Data Solutions will leverage the team’s in-depth experience in decision support, commercial sales operations, analytics and reporting. The enhanced offering will provide life science companies with a tailored execution plan to map information needs, supported by a data management platform and customizable reports and dashboards. TRINITY’s offering will be supported by experts across organizational Centers of Excellence leveraging source data, data aggregation, CRM integration, quality control, data management and customer insights. The combined solution will enable customers to manage data for the commercial transformation required to bring to market the most innovative new therapies.

“By joining forces with TRINITY, we will be able to provide a robust strategic solution for our clients,” said Kevin Kroll, COO, Bell Canyon Consulting. “The integration of our technology and data management expertise with TRINITY Commercial Data Solutions, as well as the full range of TRINITY’s advisory services, insights and analytics, will provide a true end-to-end offering for life sciences companies as they launch new products and scale their organizations.”

For more information, please visit:

Objective Capital Partners acted as the financial advisor to Bell Canyon Consulting.

About Bell Canyon Consulting
Bell Canyon’s mission is to enable life sciences clients to focus on their core competencies to drive revenues, while providing operational efficiencies and infrastructure support through custom-built information technology solutions. The company has been serving its clients since 2008, with a focus on master data management, data warehousing, business intelligence, analytics, reporting and operations.

TRINITY is a global commercialization partner to the life sciences industry, providing evidence-based solutions throughout the product lifecycle. With over 20 years of experience, TRINITY is committed to solving clients’ most challenging problems through exceptional levels of service, powerful tools, and data-driven insights. TRINITY has offices throughout the US, including Boston, New York, Princeton, Philadelphia, and San Francisco, as well as Toronto, Canada, and Gurgaon, India. In July 2019, TRINITY opened its first European Office in Munich, Germany. Trinity works with more than 160 clients annually, including 18 of the top 25 global biopharmaceutical companies. Trinity is partnered with Parthenon Capital Partners, a leading, growth-oriented private equity firm, and has over 350 professionals on staff that focus solely on the life sciences.

To learn more about how TRINITY is elevating life sciences and driving evidence to action, visit